The utility of animal models in developing immunosuppressive agents

James McDaid, Christopher J. Scott, Adrien Kissenpfennig, Huifang Chen, Paulo N. Martins

Research output: Contribution to journalReview article

5 Citations (Scopus)
681 Downloads (Pure)

Abstract

The immune system comprises an integrated network of cellular interactions. Some responses are predictable, while others are more stochastic. While in vitro the outcome of stimulating a single type of cell may be stereotyped and reproducible, in vivo this is often not the case. This phenomenon often merits the use of animal models in predicting the impact of immunosuppressant drugs. A heavy burden of responsibility lies on the shoulders of the investigator when using animal models to study immunosuppressive agents. The principles of the three R׳s: refine (less suffering,), reduce (lower animal numbers) and replace (alternative in vitro assays) must be applied, as described elsewhere in this issue. Well designed animal model experiments have allowed us to develop all the immunosuppressive agents currently available for treating autoimmune disease and transplant recipients. In this review, we examine the common animal models used in developing immunosuppressive agents, focusing on drugs used in transplant surgery. Autoimmune diseases, such as multiple sclerosis, are covered elsewhere in this issue. We look at the utility and limitations of small and large animal models in measuring potency and toxicity of immunosuppressive therapies.

Original languageEnglish
Pages (from-to)295-302
Number of pages8
JournalEuropean Journal of Pharmacology
Volume759
Early online date24 Mar 2015
DOIs
Publication statusPublished - 15 Jul 2015

Fingerprint

Immunosuppressive Agents
Animal Models
Autoimmune Diseases
Psychological Stress
Pharmaceutical Preparations
Multiple Sclerosis
Immune System
Research Personnel
Transplants
In Vitro Techniques
Therapeutics

Cite this

@article{0bddcfe059034e8d80e93b715bf6b7af,
title = "The utility of animal models in developing immunosuppressive agents",
abstract = "The immune system comprises an integrated network of cellular interactions. Some responses are predictable, while others are more stochastic. While in vitro the outcome of stimulating a single type of cell may be stereotyped and reproducible, in vivo this is often not the case. This phenomenon often merits the use of animal models in predicting the impact of immunosuppressant drugs. A heavy burden of responsibility lies on the shoulders of the investigator when using animal models to study immunosuppressive agents. The principles of the three R׳s: refine (less suffering,), reduce (lower animal numbers) and replace (alternative in vitro assays) must be applied, as described elsewhere in this issue. Well designed animal model experiments have allowed us to develop all the immunosuppressive agents currently available for treating autoimmune disease and transplant recipients. In this review, we examine the common animal models used in developing immunosuppressive agents, focusing on drugs used in transplant surgery. Autoimmune diseases, such as multiple sclerosis, are covered elsewhere in this issue. We look at the utility and limitations of small and large animal models in measuring potency and toxicity of immunosuppressive therapies.",
author = "James McDaid and Scott, {Christopher J.} and Adrien Kissenpfennig and Huifang Chen and Martins, {Paulo N.}",
year = "2015",
month = "7",
day = "15",
doi = "10.1016/j.ejphar.2015.03.025",
language = "English",
volume = "759",
pages = "295--302",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

The utility of animal models in developing immunosuppressive agents. / McDaid, James; Scott, Christopher J.; Kissenpfennig, Adrien; Chen, Huifang; Martins, Paulo N.

In: European Journal of Pharmacology, Vol. 759, 15.07.2015, p. 295-302.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The utility of animal models in developing immunosuppressive agents

AU - McDaid, James

AU - Scott, Christopher J.

AU - Kissenpfennig, Adrien

AU - Chen, Huifang

AU - Martins, Paulo N.

PY - 2015/7/15

Y1 - 2015/7/15

N2 - The immune system comprises an integrated network of cellular interactions. Some responses are predictable, while others are more stochastic. While in vitro the outcome of stimulating a single type of cell may be stereotyped and reproducible, in vivo this is often not the case. This phenomenon often merits the use of animal models in predicting the impact of immunosuppressant drugs. A heavy burden of responsibility lies on the shoulders of the investigator when using animal models to study immunosuppressive agents. The principles of the three R׳s: refine (less suffering,), reduce (lower animal numbers) and replace (alternative in vitro assays) must be applied, as described elsewhere in this issue. Well designed animal model experiments have allowed us to develop all the immunosuppressive agents currently available for treating autoimmune disease and transplant recipients. In this review, we examine the common animal models used in developing immunosuppressive agents, focusing on drugs used in transplant surgery. Autoimmune diseases, such as multiple sclerosis, are covered elsewhere in this issue. We look at the utility and limitations of small and large animal models in measuring potency and toxicity of immunosuppressive therapies.

AB - The immune system comprises an integrated network of cellular interactions. Some responses are predictable, while others are more stochastic. While in vitro the outcome of stimulating a single type of cell may be stereotyped and reproducible, in vivo this is often not the case. This phenomenon often merits the use of animal models in predicting the impact of immunosuppressant drugs. A heavy burden of responsibility lies on the shoulders of the investigator when using animal models to study immunosuppressive agents. The principles of the three R׳s: refine (less suffering,), reduce (lower animal numbers) and replace (alternative in vitro assays) must be applied, as described elsewhere in this issue. Well designed animal model experiments have allowed us to develop all the immunosuppressive agents currently available for treating autoimmune disease and transplant recipients. In this review, we examine the common animal models used in developing immunosuppressive agents, focusing on drugs used in transplant surgery. Autoimmune diseases, such as multiple sclerosis, are covered elsewhere in this issue. We look at the utility and limitations of small and large animal models in measuring potency and toxicity of immunosuppressive therapies.

U2 - 10.1016/j.ejphar.2015.03.025

DO - 10.1016/j.ejphar.2015.03.025

M3 - Review article

C2 - 25814252

VL - 759

SP - 295

EP - 302

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -